CF PharmTech Inc. will be added as a constituent stock of the Hang Seng Composite Index, effective March 9, 2026. The inclusion reflects the capital market's recognition of the company's leading position in the respiratory disease treatment market and its capabilities in inhalation drug delivery technology.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CF Pharmtech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260216-12025798), on February 16, 2026, and is solely responsible for the information contained therein.